Latest News
Via Talk Markets · February 22, 2026
Quantum computing is still a high-risk frontier, but for patient investors, these two tickers could be tomorrow's generational wealth creators.
Via The Motley Fool · February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Via The Motley Fool · February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Via The Motley Fool · February 22, 2026
Via Talk Markets · February 22, 2026
Both stocks are in the Berkshire Hathaway portfolio, selected by former CEO Warren Buffett.
Via The Motley Fool · February 22, 2026
On Friday, the Supreme Court threw out President Donald Trump's signature emergency-law tariffs, but it did not spell out how the federal government should return the $133 billion already collected from importers.
Via Benzinga · February 22, 2026
Via Talk Markets · February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Via The Motley Fool · February 22, 2026
Via Talk Markets · February 22, 2026
Via Talk Markets · February 22, 2026
Via Talk Markets · February 22, 2026
There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head.
Via The Motley Fool · February 22, 2026
Checking these boxes can help ease your claiming decision.
Via The Motley Fool · February 22, 2026
Ethereum (CRYPTO: ETH) co-founder Vitalik Buterin once revealed that his decision to leave college wasn’t a planned move driven by con
Via Benzinga · February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Via The Motley Fool · February 22, 2026
Via Talk Markets · February 22, 2026
What if you could double or even triple the market's return? Is it worth the risk?
Via The Motley Fool · February 22, 2026

DoubleVerify provides digital media measurement and analytics tools for advertisers and publishers across multiple sectors.
Via The Motley Fool · February 22, 2026
Turning a modest upfront investment in XRP into life-changing wealth is harder than it sounds.
Via The Motley Fool · February 22, 2026
Via Talk Markets · February 22, 2026
Via Talk Markets · February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Via The Motley Fool · February 22, 2026
As lawmakers question relevance of safety features amid affordability debate, this expert urged the need for regulations in the sector today.
Via Benzinga · February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Via The Motley Fool · February 22, 2026
It's about striking that perfect balance between chasing growth and protecting what you already have.
Via The Motley Fool · February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Via The Motley Fool · February 22, 2026
On Sunday, Anthony Scaramucci said he believes markets have slipped into a bear phase and argued the real issue is duration, not whether the downturn exists.
Via Benzinga · February 22, 2026
Vertiv has seen incredibly strong demand from data center operators for its cooling and power solutions.
Via The Motley Fool · February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Via The Motley Fool · February 22, 2026
In 2011, Jocelyn Elizabeth turned a $5 church-sale lamp into a seven-figure business, thanks to her YouTube channel and online marketplace.
Via Benzinga · February 22, 2026
Markets enter a critical week dominated by Wednesday's Nvidia earnings and escalating geopolitical tensions as rising U.S.-Iran hostilities push oil prices higher.
Via Barchart.com · February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Via The Motley Fool · February 22, 2026
The company's years of beating the market aren't over yet.
Via The Motley Fool · February 22, 2026

This diversified utility delivers natural gas, electric, and propane services to customers across the eastern U.S.
Via The Motley Fool · February 22, 2026
Cleveland may sound like a sleepy little midwestern town. However, it's anything but sleepy.
Via The Motley Fool · February 22, 2026
This latest purchase offers Druckenmiller another AI winner.
Via The Motley Fool · February 22, 2026
Via Benzinga · February 22, 2026
Will the tech giant be able to follow through on its aspirations?
Via The Motley Fool · February 22, 2026

SSR Mining is a global precious metals producer with operations spanning gold, silver, and base metals across four continents.
Via The Motley Fool · February 22, 2026
The Direxion Daily Financial Bear 3X Shares is still useful for some traders, but don't expect it to act like 2008 is back.
Via The Motley Fool · February 22, 2026
With high-occupancy and long-term lease terms, this REIT is built for stability. But, is it still a buy?
Via The Motley Fool · February 22, 2026
JPMorgan Chase & Co. (NYSE: JPM) acknowledged in a court filing that it shut down bank accounts tied to President Donald Trump and several of his businesses after the Jan. 6, 2021, Capitol riot, a point now sitting at the center of Trump's $5 billion lawsuit against the lender and its chief executive.
Via Benzinga · February 22, 2026
Iran's supreme leader, Ayatollah Ali Khamenei, has elevated Ali Larijani into a de facto crisis manager role as Tehran braces for a possible clash with US and tries to keep the state functioning under pressure.
Via Benzinga · February 22, 2026
Bill Ackman just bet big on Meta Platforms.
Via The Motley Fool · February 22, 2026
Inflation data shows stubborn inflation, affecting savings and retirement readiness. Men have higher savings but women face structural realities.
Via Benzinga · February 22, 2026
It's time for investors to think about the progression of autonomous vehicle technology.
Via The Motley Fool · February 22, 2026
Palo Alto's business is going from strength to strength as it prepares customers for an increasingly dangerous cyber landscape.
Via The Motley Fool · February 22, 2026